Law, ethics and medicine
Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
Other content recommended for you
- Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
- Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis
- Mucopolysaccharidosis type I disguised as rickets
- Commissioning for rare diseases: view from the frontline
- Should rare diseases get special treatment?
- Clinical course of sly syndrome (mucopolysaccharidosis type VII)
- ‘Doctor Google’ ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres
- Orphan drugs and the NHS: should we value rarity?